This article is only available in the PDF format. Download the PDF to view the article, as well as its associated figures and tables.
A 66-year-old African-American woman with essential hypertension began using the clonidine hydrochloride transdermal patch (Catapres-TTS2 [transdermal therapeutic system: clonidine hydrochloride, 0.2 mg/d for 1 week]) in May 1989. Previously, she had used other antihypertensive medications, including various combinations of calcium channel blockers, β-blockers, diuretics, and angiotensin-converting enzyme inhibitors, with poor control of blood pressure. Presently, her blood pressure is better controlled, in the range of 140/90 mm Hg, with a clonidine transdermal patch (Catapres-TTS2), chlorthalidone (100 mg/d), betaxolol hydrochloride (Kerlone, 10 mg/d), and potassium chloride (Micro-K, 10 mmol/L twice a day).
Asymptomatic skin depigmentation was first noted about 1 year after therapy was initiated. The Figure shows the area of depigmentation in the left upper chest area. A similar area of depigmentation is in the right upper chest area. These sites have not been used for application of the transdermal patch for about 4 years. Despite that, repigmentation of the
Doe N, Seth S, Hebert LA. Skin Depigmentation Related to Transdermal Clonidine Therapy. Arch Intern Med. 1995;155(19):2129. doi:10.1001/archinte.1995.00430190125021
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: